HM
TVTX icon

HealthCor Management’s Travere Therapeutics TVTX Stock Holding History

HealthCor Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-618,520
Closed -$15.4M – 105
2021
Q1 		$15.4M Buy
+618,520
New +$17.1M 0.55% 47

Other funds holding TVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

HealthCor Management's TVTX Position: Q2 2021 in Review

HealthCor Management sold out of Travere Therapeutics (TVTX) in Q2 2021, closing a stake of 618,520 shares — an estimated $15.4M sold.

HealthCor Management first reported a position in TVTX in Q1 2021 and held it in 1 quarter. The position peaked at $15.4M in Q1 2021. 136 funds tracked by Wall St. Rank hold TVTX as of Q2 2021.

  • HealthCor Management reported no remaining Travere Therapeutics position as of Q2 2021 after selling out during the quarter.
  • HealthCor Management sold 618,520 Travere Therapeutics shares in Q2 2021, an estimated $15.4M.
  • HealthCor Management first reported a position in Travere Therapeutics in Q1 2021 and held it in 1 quarter.
  • HealthCor Management's Travere Therapeutics position peaked at $15.4M in Q1 2021.
  • 136 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2021.

Based on HealthCor Management's 13F filing for Q2 2021, filed 16 Aug 2021.